Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript
Source: SeekingAlpha
2025-12-23 08:36:07 ET
Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma December 23, 2025 5:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript
Orexo AB ADR
NASDAQ: ORXOY
ORXOY Trading
237.22% G/L:
$2.60 Last:
100 Volume:
$2.60 Open:
ORXOY Latest News
March 06, 2026 10:29:00 am
Orexo changes the organizational structure and management team to increase focus on development of new products
September 05, 2025 08:28:00 am
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
